Medical wellness programs
A dual-incretin synthetic peptide that activates both the GIP and GLP-1 receptor pathways. Prepared by a state-licensed 503A compounding pharmacy when your provider determines a personalized formulation fits your biology. Telehealth in Michigan, Florida, Alabama, and Mississippi. From $265/mo. Free 20-minute consultation.
Compounded Tirzepatide
from $265/mo
Medication, monthly check-ins, labs and dose titration.
Medically reviewed by
Dr. Erald Lula, MD, MPH
Triple Board-Certified: Internal Medicine, Obesity Medicine, Lifestyle Medicine
Last reviewed: Bio
NuHealth’s tirzepatide program is a program, not a prescription. Every plan combines the compounded dual-incretin medication, supervised provider care, and the biology check that keeps a GIP + GLP-1 protocol calibrated over time.
The dual-incretin medication
A synthetic peptide that activates both GIP and GLP-1 receptors, prepared by a state-licensed 503A pharmacy on a per-prescription basis. Shipped discreetly after provider authorization.
The provider
Licensed in your state. Free 20-minute consultation reviewing your full medical history. Monthly check-ins and direct provider messaging.
The biology check
Baseline labs before any prescription. Gradual titration over the first 16 to 20 weeks across both pathways. Quarterly labs and response tracking with your provider.
“Pricing posted up front: Compounded Tirzepatide from $265 / month. Your provider determines whether a personalized compounded program is clinically appropriate for you at the consultation.”
Tirzepatide is a synthetic peptide that activates two incretin receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Semaglutide is a single-pathway GLP-1 agonist; tirzepatide is dual.
A “compounded” medication is one prepared by a state-licensed compounding pharmacy on a prescription-by-prescription basis. NuHealth’s compounded tirzepatide is prepared by a 503A compounding pharmacy when your NuHealth provider determines that a personalized formulation fits your clinical situation. This per-patient framework is what allows ongoing compounding of tirzepatide under current FDA rules.
Compounded tirzepatide is not FDA-approved as a finished drug product, and is not Mounjaro® or Zepbound® (the FDA-approved finished drugs by Eli Lilly). Your NuHealth provider will explain how this affects your treatment plan during your consultation.
How it works in the body
GIP pathway
Activates the GIP receptor — glucose-dependent insulinotropic polypeptide.
GLP-1 pathway
Activates the GLP-1 receptor — the same target a single-incretin GLP-1 hits alone.
Energy + appetite regulation
Together the two pathways influence satiety, glucose handling, and energy.
A board-certified physician reviews your medical history, weight history, prior GLP-1 response (if any), and any medications or conditions that may affect candidacy for a dual-incretin program. If you are not a candidate for compounded tirzepatide, your provider discusses alternatives. The consultation itself is free.
Your provider orders baseline labs (typically HbA1c, lipid panel, kidney function, and a metabolic panel), reviews your results, and confirms whether a personalized compounded tirzepatide program is appropriate for your biology. If your provider authorizes treatment, your prescription is sent to our 503A compounding pharmacy partner.
Monthly check-ins with your provider. Quarterly labs to track how your body responds across both pathways. Your provider adjusts dose, slows titration, or recommends a different protocol entirely if side effects are limiting. You can message your provider directly between appointments.
Throughout, your treatment plan is the responsibility of your NuHealth provider; informed by your full medical history, labs, and response across both incretin pathways.
Candidacy
Compounded tirzepatide may be appropriate for adults whose provider determines that a dual-incretin medication fits their clinical situation. Here is how candidacy is generally framed before your consultation.
Provider-assessed at your consultation
Many patients describe a quieting of food noise plus steadier mid-day energy. The GLP-1 pathway is the one a single-incretin agonist hits; the GIP pathway also influences insulin secretion, so glucose handling often feels more stable between meals. Individual response varies; your provider tracks your specific timeline at every check-in.
Weeks 1-2
Starting dose · 2.5 mg weekly
Your provider starts at 2.5 mg weekly so your body adjusts to dual-receptor onboarding. Many patients describe early appetite changes; mild nausea is the most common side effect and usually resolves.
Week 4
First titration · often 5 mg
If the starting dose is well-tolerated, your provider may step you up (commonly to 5 mg). A check-in confirms how your body responds across both pathways.
Week 12
7.5-10 mg range · full rhythm
By three months, many patients have settled into a stable dose with their provider. Your provider reviews progress, side effects, and labs.
Week 24
Outcomes review · 12.5-15 mg band
Around six months your provider does a full outcomes review. Some patients move to a lower-dose maintenance phase; others continue at a 12.5 or 15 mg maintenance band.
The pattern above is what patients commonly describe. It is not a guarantee of outcome. Your provider tailors the plan to your specific metabolic profile, labs, and goals.
The program at a glance
Tirzepatide acts on two incretin pathways. Your provider starts you at a low dose and titrates gradually, reviewing how you respond at every check-in. Compounded tirzepatide is prepared per-patient by a state-licensed 503A pharmacy. Individual results vary — your plan is built around your biology, under medical supervision.
Pharmacy
503A
State-licensed compounding
Provider response
<24h
Typical reply on the patient portal
States
4
MI · FL · AL · MS
Google rating
5.0★
From verified patients
The medication
Compounded tirzepatide
Prepared to your provider’s prescription by a state-licensed 503A compounding pharmacy.
Free 20-minute consultation · Provider determines candidacy
Pricing
The compounded tirzepatide program covers the medication, provider check-ins, labs, and dose titration across both GIP and GLP-1 pathways. Transparent pricing, no insurance middleman.
Free consultation
Free. No charge for the visit, whatever the outcome.
No hidden fees
The monthly price covers medication, provider care, and labs.
Cancel anytime
Programs continue only when you and your provider agree.
Or join NuHealth+ from $99/mo and save 15% on this program.
GIP + GLP-1 dual receptor agonist, prepared per prescription.
3-month starter program
A free 20-minute provider consultation precedes any prescription.
CareCredit · Financing partner
GLP-1 programs run $125–$265 a month. With CareCredit, split the medication, labs, and follow-through over a longer schedule. Prequalification has no impact on your credit score.
Check your prequalificationCareCredit is a financing product from Synchrony Bank. NuHealth Medical Wellness does not own, operate, or set the terms of CareCredit. Approval, rates, and terms are determined by Synchrony at application.
In-person consults for patients in metro Detroit. Telehealth in Michigan, Florida, Alabama, and Mississippi. The medication ships to your door; when you need to walk in for labs, an in-person visit, or a dose discussion, our clinic is on Woodward, between Birmingham and Berkley.
NuHealth Medical Wellness30301 Woodward Ave, Suite 240Three topics, in plain language. If you do not see your question, the free consultation is the place to ask it.
Tirzepatide is a synthetic peptide that activates two incretin receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). A compounded preparation is one prepared by a state-licensed compounding pharmacy on a per-prescription basis. NuHealth’s compounded tirzepatide is prepared by our 503A pharmacy partner when your provider determines a personalized formulation is appropriate for your situation. It is not FDA-approved as a finished drug product.
Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both the GIP and the GLP-1 receptors. Some patients respond better to one approach versus the other; the right choice depends on your medical history, prior treatment response, and lab profile. Your NuHealth provider helps determine which medication fits your specific situation.
Many patients describe noticing appetite changes within the first 1–2 weeks. Measurable changes typically appear later. Your provider tracks your specific timeline at every check-in. Individual response varies.
$265/month. The monthly price includes the medication (when prescribed), provider check-ins, lab orders, dose titration, and direct provider messaging. The 20-minute provider consultation is free. NuHealth does not bill insurance.
No. NuHealth’s compounded tirzepatide is not Mounjaro® or Zepbound®. Those are FDA-approved finished drug products manufactured and tested by Eli Lilly (Mounjaro for type 2 diabetes, Zepbound for chronic weight management). NuHealth’s compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy on a per-prescription basis and is not FDA-approved as a finished drug product. Clinical-trial outcomes from FDA-approved branded products do not transfer to compounded preparations. Your provider will explain the distinction during your consultation.
If you remember within 4 days of your scheduled dose, take it as soon as you remember and continue your normal weekly schedule. If more than 4 days have passed, skip the missed dose and continue with your next scheduled one. Don’t double up. If you have questions about dosing, message your provider.
Yes — tirzepatide is a subcutaneous injection, given once a week. The needles are very fine (similar to insulin pens). Your provider walks you through the technique at your first appointment.
Many patients regain some weight when they stop. Your provider will work with you on a tapering plan if you decide to discontinue. Some patients move to a lower-dose maintenance schedule with their provider; others step down over months as lifestyle changes take hold. The plan is individualized.
From a patient
“After a year of partial progress on a single-pathway GLP-1, switching changed the whole conversation about my biology.”
Tom L.
Tirzepatide Program
Starting
312 lbs
Current
252 lbs
16 weeks in program
The next step
NuHealth provides telehealth care to adults in Michigan, Florida, Alabama, and Mississippi, with in-person consultations available at our Royal Oak, MI clinic. Start with a free 20-minute consultation; your provider determines candidacy for the dual-incretin program based on your medical history and labs.
Or join NuHealth+ from $99/mo and save 15% on this program.